Juno Therapeutics Inc (JUNO) is Downgraded by FBR & Co. to Mkt Perform, Price Target at $30

Juno Therapeutics Inc (JUNO) was Downgraded by FBR & Co. to ” Mkt Perform” and the brokerage firm has set the Price Target at $30. Earlier the firm had a rating of “Outperform ” on the company shares. FBR & Co. advised their investors in a research report released on Nov 23, 2016.

On the company’s financial health, Juno Therapeutics Inc reported $-0.57 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Nov 9, 2016. Analyst had a consensus of $-0.58. The company had revenue of $20.80 million for the quarter, compared to analysts expectations of $11.31 million. The company’s revenue was up 1200.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.26 EPS.

Juno Therapeutics Inc closed down -0.68 points or -2.22% at $29.93 with 10,31,498 shares getting traded on Monday. Post opening the session at $30.69, the shares hit an intraday low of $29.59 and an intraday high of $30.9399 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

In a different news, on Nov 10, 2016, Robert Azelby (EVP & Chief Commercial Officer) sold 12,921 shares at $24.14 per share price. According to the SEC, on Sep 29, 2016, Hans Edgar Bishop (CEO & President) sold 44,000 shares at $33.00 per share price. On Jun 24, 2016, Richard Klausner (director) sold 12,000 shares at $40.71 per share price, according to the Form-4 filing with the securities and exchange commission.

Juno Therapeutics Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates JCAR015 JCAR017 and JCAR014 utilize CAR technology to target CD19 a protein expressed on the surface of various B cell leukemias and lymphomas. Juno’s other product candidates include JCAR018: CD22 JCAR023: L1CAM (CD171) JCAR020: MUC-16 / IL-12 ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML myelodysplasic syndrome and chronic myeloid leukemia.

Juno Therapeutics Inc

Leave a Reply

Juno Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Juno Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.